Kleo Pharmaceuticals, Inc. logo

Kleo Pharmaceuticals, Inc.

Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics. Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs) are designed to direct your immune system to fight specific disease causing cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.kleopharmaceuticals.com
Disease Focus
STOCK CODENon Listed
Address
25 Science Park, Suite 2D150 Munson Street, CT 06511
New Haven
United States
Email
Contact Number
+1 203-691-6361

Kleo Pharmaceuticals, Inc. develops and markets immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers.

Kleo was formed on the basis of intellectual property from the Spiegel Lab at Yale University and was founded by Dr. David Spiegel and Roy Prieb and is focused on developing a new class of targeted immunotherapies. The platform technology licensed from Yale University to Kleo involve other targets and intellectual property related to ARMS and SyAMS.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/kleo-pharmaceuticals-inc.” connections=”true” suffix=””]

Kleos two novel platforms Antibody Recruiting Molecules (ARMs_) and Synthetic Antibody Mimics (SyAMs_)  are designed to direct a patients immune system to fight specific disease-causing cells.

In July 2017, PeptiDream Inc. and Kleo signed agreement to co-develop proprietary immune-oncology products. Under the terms, PeptiDream will use its proprietary Peptide Discovery Platform System (_PDPSÓ) technology to identify macrocyclic/ constrained peptides against multiple oncology targets of interest selected by Kleo, and to optimize hit peptides into optimized binders that will be engineered by Kleo into novel ARM and SyAM products. Kleo will have the right to develop and commercialize all compounds resulting from the collaboration. PeptiDream is eligible to receive a tiered share of proceeds from any products that arise from the collaboration based on degree to which PeptiDream funds development of the product. Specific financial terms were not disclosed.

In Sep 2016, Klero Pharmaceuticals raised $11 Mn in a series A round. The round was led by Biohaven Pharmaceutical Holding Company.